Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18735399 | 0.92 | CYP2C9 (0.34) | CYP2C9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18735109 | 0.92 | CYP2C9 (0.34) | CYP2C9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24454086 | 0.91 | CAPN1 (0.35) | MEN1KMT2A | |
| SCHEMBL18735395 | 0.88 | SMN1; SMN2 (0.33) | CYP2C9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18735396 | 0.88 | SMN1; SMN2 (0.33) | CYP2C9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18735186 | 0.85 | CYP2C9 (0.30) | CYP2C9 | |
| SCHEMBL18735142 | 0.83 | KMT2A (0.39) | CYP2C9KMT2A | |
| SCHEMBL18734934 | 0.83 | — | — | |
| SCHEMBL18735180 | 0.82 | ALOX15 (0.32) | LMNA | |
| SCHEMBL18734935 | 0.81 | KMT2A (0.32) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3391941-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3391941-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2021-12-30 | — | — | US | disclosed |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2021-12-30 | — | — | US | disclosed |
| US-11147789-B2 | Cell-permeable succinate compounds | Abliva Ab (SE) | 2021-10-19 | — | — | US | disclosed |
| US-11147789-B2 | Cell-permeable succinate compounds | Abliva Ab (SE) | 2021-10-19 | — | — | US | disclosed |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | NEUROVIVE PHARMACEUTICAL AB (SE) | 2019-06-04 | — | — | US | disclosed |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | NEUROVIVE PHARMACEUTICAL AB (SE) | 2019-06-04 | — | — | US | disclosed |
| EP-3391941-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NeuroVive Pharmaceutical AB (SE) | 2018-10-24 | — | — | EP | disclosed |
| EP-3129016-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-06-06 | — | — | EP | disclosed |
| EP-3129016-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | Abliva Ab (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | Abliva Ab (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| EP-3129016-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Neurovive Pharmaceutical AB (SE) | 2017-02-15 | — | — | EP | disclosed |
| EP-3129058-A1 | SUCCINATE PRODRUGS FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS OR DRUG-INDUCED SIDE-EFFECTS DUE TO COMPLEX I-RELATED IMPAIRMENT OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION | Neurovive Pharmaceutical AB (SE) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015155238-A1 | SUCCINATE PRODRUGS FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS OR DRUG-INDUCED SIDE-EFFECTS DUE TO COMPLEX I-RELATED IMPAIRMENT OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155231-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | SLC25A1, SLC25A11, CS | CYP2C9 2502/4885MEN1 3013/4885KMT2A 2980/4885 |
| US-11147789-B2 | Cell-permeable succinate compounds | SLC25A1, SLC25A11, SLC25A21 | CYP2C9 1992/4885MEN1 2964/4885KMT2A 2878/4885 |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | CS, MDH2, SLC25A11 | CYP2C9 350/4885MEN1 2945/4885KMT2A 2705/4885 |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | CS, MDH2, SLC25A11 | CYP2C9 350/4885MEN1 2945/4885KMT2A 2705/4885 |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | SLC25A1, SLC25A11, CS | CYP2C9 2468/4885MEN1 3162/4885KMT2A 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.